Pharma Articles and Journals
Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med. 2005 Aug;118(8):881-4.
Abstract
Bekelman JE, Li Y, Gross CP. Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review. JAMA 2003 Jan;289(4):454-465.
Abstract
Brody H. The Company We Keep: Why Physicians Should Refuse to See Pharmaceutical Representatives. Ann Fam Med. 2005 3:82-85.
Abstract and Full Text
Campbell E, Gruen R, Mountford J, et. al. A national survey of physician–industry relationships. NEJM 2007 Apr 26;356(17):1742-50.
Abstract Full Text
Chew, LD, et al. A Physician Survey of the Effect of Drug Sample Availability on Physicians' Behavior. J Gen Int Med. 2000;15:478-483
Abstract Full Text
Chimonas S, Brennan T, Rothman D. Physicians and drug representatives: exploring the dynamics of the relationship. JGIM 2007 Feb;22(2):184–190
Abstract and Full Text
Dominick L. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med 2007;5(1):6-13.
Full Text
Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007 Apr 24;4(4):e150.
Full Text
Grande D. Prescriber Profiling: Time to Call It Quits. Annals of Int Med. 2007 May; 146(10):751-752.
Full Text
Katz D, Caplan AL, Merz JF. All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving. American Journal of Bioethics 2003 Summer;3(3):39-46.
Abstract
Jeanne Lenzer and Shannon Brownlee. Naming Names: is there an (unbiased) doctor in the house? BMJ 2008; 337:a930 (23 July 2008)
Abstract Full Text
Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ 1993;149(10):1401-7.
Abstract Full Text
Mansfield P, Lexchin J, Wen L, Grandori L, McCoy C, Hoffman J, et. al. Educating health professionals about drug and device promotion: advocates’ recommendations. PLoS Med. 2006 November;3(11):1988-1991.
Full Text
Mather C. The pipeline and the porcupine: alternate metaphors of the physician-industry relationship. Soc Sci Med. 2005 Mar;60(6):1323-34.
Abstract
Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q. 2004 Sep;18(3):325-56.
Abstract
Pegler S and Underhill J. Evaluating promotional material from industry: an evidence-based approach. The Pharmaceutical Journal. 2005 March 5;274(7339): 271-274.
Full Text
Ross J, Hill K, Egilman D, Krumholz H. Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents from Rofecoxib Litigation. JAMA 2008 Apr 16;299(15):1800-1812.
Abstract Accompanied JAMA editorial Extract
Ross J, Lackner J, Lurie P, et. al. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007 Mar 21;297(11):1216-1222.
Abstract Full Text
Shaughnessy AF, Slawson DC, Bennett JH. Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion. J Gen Intern Med. 1994 Oct;9(10):563-8.Full Text
Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283:373-380.
Abstract Full Text
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. Am J Health Syst Pharm. 2002 Jan 1;59(1):42-9.
Abstract
Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med. 2005 Aug;20(8):777-86.
Abstract and Full Text
Return to How to Become Unbranded Homepage